182 related articles for article (PubMed ID: 33265979)
1. Selective Binding of Cyclodextrins with Leflunomide and Its Pharmacologically Active Metabolite Teriflunomide.
Terekhova I; Kritskiy I; Agafonov M; Kumeev R; Martínez-Cortés C; Pérez-Sánchez H
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33265979
[TBL] [Abstract][Full Text] [Related]
2. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
Heidarian R; Zahedi-Tabrizi M
Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
[TBL] [Abstract][Full Text] [Related]
3. On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
Kujawski J; Bernard MK; Jodłowska E; Czaja K; Drabińska B
J Mol Model; 2015 May; 21(5):105. PubMed ID: 25851105
[TBL] [Abstract][Full Text] [Related]
4. γ-Cyclodextrin-metal organic frameworks as efficient microcontainers for encapsulation of leflunomide and acceleration of its transformation into teriflunomide.
Kritskiy I; Volkova T; Surov A; Terekhova I
Carbohydr Polym; 2019 Jul; 216():224-230. PubMed ID: 31047061
[TBL] [Abstract][Full Text] [Related]
5. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
Rule GS; Rockwood AL; Johnson-Davis KL
Methods Mol Biol; 2019; 1872():75-83. PubMed ID: 30350281
[TBL] [Abstract][Full Text] [Related]
6. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide.
Yao X; Liu Y; Song L; Jiang J; Xiao F; Liu D; Hu P
Biomed Chromatogr; 2019 Mar; 33(3):e4420. PubMed ID: 30362147
[TBL] [Abstract][Full Text] [Related]
7. Detection of in Vitro Metabolite Formation of Leflunomide: A Fluorescence Dynamics and Electronic Structure Study.
Sharma P; Gangopadhyay D; Mishra PC; Mishra H; Singh RK
J Med Chem; 2016 Apr; 59(7):3418-26. PubMed ID: 27007481
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Bergner R; Peters L; Schmitt V; Löffler C
Clin Rheumatol; 2013 Feb; 32(2):267-70. PubMed ID: 23179005
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil/cyclodextrin complexation: stability constants, thermodynamics, and guest-host interactions probed by 1H NMR and molecular modeling studies.
Al Omari MM; Zughul MB; Davies JE; Badwan AA
J Pharm Biomed Anal; 2006 Jun; 41(3):857-65. PubMed ID: 16527440
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
13. Fexofenadine/cyclodextrin inclusion complexation: phase solubility, thermodynamic, physicochemical, and computational analysis.
Omari MM; Badwan AA; Zughul MB; Eric J; Davies D
Drug Dev Ind Pharm; 2007 Nov; 33(11):1205-15. PubMed ID: 18058317
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
16. Thermodynamic insight into the origin of the inclusion of monosulfonated isomers of triphenylphosphine into the beta-cyclodextrin cavity.
Canipelle M; Caron L; Christine C; Tilloy S; Monflier E
Carbohydr Res; 2002 Feb; 337(3):281-7. PubMed ID: 11844499
[TBL] [Abstract][Full Text] [Related]
17. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
Yao X; Wu Y; Jiang J; Hu P; Liu D; Chen X
Clin Drug Investig; 2019 Jul; 39(7):643-651. PubMed ID: 31016613
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
[TBL] [Abstract][Full Text] [Related]
19. Multimodal inclusion complexes between barbiturates and 2-hydroxypropyl-beta-cyclodextrin in aqueous solution: isothermal titration microcalorimetry, (13)C NMR spectrometry, and molecular dynamics simulation.
Aki H; Niiya T; Iwase Y; Yamamoto M
J Pharm Sci; 2001 Aug; 90(8):1186-97. PubMed ID: 11536223
[TBL] [Abstract][Full Text] [Related]
20. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Bae J; Park JW
Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
